By Colin Kellaher

GlaxoSmithKline PLC (GSK.LN, GSK) on Tuesday said the U.S. Food and Drug Administration granted priority review to its biologics license application for belantamab mafodotin in a form of the blood cancer multiple myeloma.

The U.K. drug maker said the application covers the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 21, 2020 10:38 ET (15:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni GSK (LSE:GSK)
Storico
Da Giu 2026 a Lug 2026 Clicca qui per i Grafici di GSK
Grafico Azioni GSK (LSE:GSK)
Storico
Da Lug 2025 a Lug 2026 Clicca qui per i Grafici di GSK